NXT007 vs. EmicizumabA Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

Sponsor:

Hoffmann-La Roche

Code:

NCT07416604

Conditions

Hemophilia A

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

NXT007

Emicizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-21. This information was provided to ClinicalTrials.gov by Hoffmann-La Roche on 2026-08-06.